EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension

Yoshio Iwashima iD, Hiromichi Fukushima, Takeshi Horio, Tatemitsu Rai, Toshihiko Ishimitsu

The Journal of Clinical Hypertension · 2023

DOI: 10.1111/jch.14635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, 2023. Verfasst von Yoshio Iwashima und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kansai Medical University Kori Hospital, Neyagawa, Osaka, Japan. Hauptthemen laut MEDLINE: Hypertension, Heart Failure. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment, home blood pressure (BP), BP values during hemodialysis, and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level were measured. The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ± 64 mg/day. After 3 months, significant reductions in mean morning home BP (155 ± 17/80 ± 12 to 147 ± 16/76 ± 11 mmHg), mean nighttime home systolic BP (153 ± 19 to 144 ± 16 mmHg), and median (IQRs) NT‐proBNP level [8124 (2620–13 394) to 6271 (1570–9591) pg/mL] were observed (all P < .05), whereas BP values during hemodialysis did not change significantly. In hemodialysis patients, except for hypotension, sacubitril/valsartan was generally well tolerated, effectively controlled out‐of‐office BP, and improved NT‐proBNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionHeart FailureHumansMaleAgedTetrazolesValsartanAminobutyratesBiphenyl CompoundsAngiotensin Receptor AntagonistsDrug CombinationsStroke VolumeBenzimidazolesOxadiazoles

Stichwörter der Autor:innen

N-terminal pro-brain natriuretic peptidehemodialysishome blood pressuresacubitril/valsartan

Substanzen

TetrazolesValsartanAminobutyratesBiphenyl CompoundsAngiotensin Receptor AntagonistsDrug CombinationsazilsartanBenzimidazolesOxadiazolessacubitril

Autor:innen und Institutionen

  • Department of Internal Medicine, Kansai Medical University Kori Hospital, Neyagawa, Osaka, Japan.
  • Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan.
  • Division of Internal Medicine, Mooka Hospital, Mooka, Tochigi, Japan.
  • Department of Cardiovascular Medicine, Ishikiriseiki Hospital, Higashiosaka, Osaka, Japan.

ORCID-Profile: Yoshio Iwashima

Zitieren

APA

Iwashima, Y., Fukushima, H., Horio, T., Rai, T., & Ishimitsu, T. (2023). Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14635

Vancouver

Iwashima Y, Fukushima H, Horio T, Rai T, Ishimitsu T. Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension. The Journal of Clinical Hypertension. 2023. doi:10.1111/jch.14635

BibTeX
@article{Iwashima2023,
  author = {Iwashima, Yoshio and Fukushima, Hiromichi and Horio, Takeshi and Rai, Tatemitsu and Ishimitsu, Toshihiko},
  title = {Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension},
  journal = {The Journal of Clinical Hypertension},
  year = {2023},
  doi = {10.1111/jch.14635}
}
Kostenlos starten →